Published in Vasc Cell on July 05, 2012
Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. Am J Physiol Renal Physiol (2014) 0.88
Pericyte-fibroblast transition promotes tumor growth and metastasis. Proc Natl Acad Sci U S A (2016) 0.78
Exosomes mediate the acquisition of the disease phenotypes by cells with normal genome in tuberous sclerosis complex. Oncogene (2015) 0.77
Synergistic Inhibition of Tumor Necrosis Factor-Alpha-Stimulated Pro-Inflammatory Cytokine Expression in HaCaT Cells by a Combination of Rapamycin and Mycophenolic Acid. Ann Dermatol (2015) 0.75
Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med (2008) 9.64
Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol (2002) 8.04
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell (2005) 7.75
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res (2005) 7.34
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat Cell Biol (2003) 6.32
mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol (2006) 5.06
Rapamycin causes regression of astrocytomas in tuberous sclerosis complex. Ann Neurol (2006) 4.24
Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation. A role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem (2002) 4.19
TSC2 regulates VEGF through mTOR-dependent and -independent pathways. Cancer Cell (2003) 4.13
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Mutation in TSC2 and activation of mammalian target of rapamycin signalling pathway in renal angiomyolipoma. Lancet (2003) 2.09
Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res (2008) 1.72
Rhebbing up mTOR: new insights on TSC1 and TSC2, and the pathogenesis of tuberous sclerosis. Cancer Biol Ther (2003) 1.58
Regulation of TSC2 by 14-3-3 binding. J Biol Chem (2002) 1.38
Inflammatory processes in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex. Epilepsy Res (2007) 1.36
The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development. J Clin Invest (2009) 1.17
Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol (2009) 1.15
MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development. J Exp Med (2005) 1.14
Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem (2004) 1.04
Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin. Cancer Res (2005) 1.03
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo. Clin Cancer Res (2008) 1.03
Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB. J Biol Chem (2005) 0.90
Functional tyrosine kinase inhibitor profiling: a generally applicable method points to a novel role of platelet-derived growth factor receptor-beta in tuberous sclerosis. Am J Pathol (2002) 0.84
Measurements of TSC2 GAP activity toward Rheb. Methods Enzymol (2006) 0.81
Down-regulation of MMP-2 expression due to inhibition of receptor tyrosine kinases by imatinib and carboplatin in HNSCC. Oncol Rep (2011) 0.80
Effect of PCI on quality of life in patients with stable coronary disease. N Engl J Med (2008) 7.75
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol (2009) 3.55
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol (2010) 3.43
Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med (2011) 3.09
Adult mouse epicardium modulates myocardial injury by secreting paracrine factors. J Clin Invest (2011) 2.99
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest (2009) 2.52
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem (2003) 2.44
PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest (2002) 2.31
Staphylococcus aureus bacteremia and endocarditis: the Grady Memorial Hospital experience with methicillin-sensitive S aureus and methicillin-resistant S aureus bacteremia. Am Heart J (2004) 2.25
Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis. J Biol Chem (2003) 2.23
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18
Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol (2008) 2.17
The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res (2005) 2.14
Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A (2009) 2.08
The chromosome 9p21 risk locus is associated with angiographic severity and progression of coronary artery disease. Eur Heart J (2010) 2.04
Post-traumatic stress disorder and incidence of coronary heart disease: a twin study. J Am Coll Cardiol (2013) 2.03
Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A (2004) 1.98
The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol (2013) 1.97
The impact of pruritus on quality of life: the skin equivalent of pain. Arch Dermatol (2011) 1.96
Patient literacy and question-asking behavior during the medical encounter: a mixed-methods analysis. J Gen Intern Med (2007) 1.88
Sex differences in hospital mortality after coronary artery bypass surgery: evidence for a higher mortality in younger women. Circulation (2002) 1.85
Regulation of CXCR4-mediated chemotaxis and chemoinvasion of breast cancer cells. Oncogene (2004) 1.83
A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal (2011) 1.79
Aggregate risk score based on markers of inflammation, cell stress, and coagulation is an independent predictor of adverse cardiovascular outcomes. J Am Coll Cardiol (2013) 1.77
Mohs micrographic surgery vs traditional surgical excision: a cost comparison analysis. Arch Dermatol (2004) 1.75
Heritability and seasonal variability of vitamin D concentrations in male twins. Am J Clin Nutr (2010) 1.73
Increased expression of urinary matrix metalloproteinases parallels the extent and activity of vascular anomalies. Pediatrics (2005) 1.72
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol (2006) 1.72
Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res (2008) 1.72
Bmi-1 cooperates with H-Ras to transform human mammary epithelial cells via dysregulation of multiple growth-regulatory pathways. Cancer Res (2007) 1.70
ErbB2 degradation mediated by the co-chaperone protein CHIP. J Biol Chem (2003) 1.70
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest (2009) 1.68
Factors affecting resident career decisions: the first five years of the society for investigative dermatology resident retreat. J Invest Dermatol (2010) 1.67
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Prognostic value of stress myocardial perfusion positron emission tomography: results from a multicenter observational registry. J Am Coll Cardiol (2012) 1.63
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
Making the cut: protease-mediated regulation of angiogenesis. Exp Cell Res (2006) 1.59
Comparison of diagnostic and management sensitivity to melanoma between dermatologists and MelaFind: a pilot study. Arch Dermatol (2012) 1.58
Shared as well as distinct roles of EHD proteins revealed by biochemical and functional comparisons in mammalian cells and C. elegans. BMC Cell Biol (2007) 1.58
The Cbl family and other ubiquitin ligases: destructive forces in control of antigen receptor signaling. Immunity (2004) 1.58
Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol (2010) 1.57
Quantitative and comparative assessment of learning in a tongue-operated computer input device. IEEE Trans Inf Technol Biomed (2011) 1.57
The impact of total body photography on biopsy rate in patients from a pigmented lesion clinic. J Am Acad Dermatol (2007) 1.56
Influence of sex on risk stratification with stress myocardial perfusion Rb-82 positron emission tomography: Results from the PET (Positron Emission Tomography) Prognosis Multicenter Registry. J Am Coll Cardiol (2013) 1.54
Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species. Clin Cancer Res (2008) 1.54
Association of a genetic risk score with prevalent and incident myocardial infarction in subjects undergoing coronary angiography. Circ Cardiovasc Genet (2012) 1.54
Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal (2009) 1.53
Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol (2004) 1.52
Forty-year journey of angiogenesis translational research. Sci Transl Med (2011) 1.51
ADAM 12 cleaves extracellular matrix proteins and correlates with cancer status and stage. J Biol Chem (2004) 1.51
Adherence to the mediterranean diet is inversely associated with circulating interleukin-6 among middle-aged men: a twin study. Circulation (2007) 1.51
Modeling breast cancer-associated c-Src and EGFR overexpression in human MECs: c-Src and EGFR cooperatively promote aberrant three-dimensional acinar structure and invasive behavior. Cancer Res (2007) 1.51
Endogenous angiogenesis inhibitors prevent adaptive capillary growth in left ventricular pressure overload hypertrophy. Ann Thorac Surg (2012) 1.49
Effects of targeted papillary muscle relocation on mitral leaflet tenting and coaptation. Ann Thorac Surg (2012) 1.46
Prognostic significance of impaired chronotropic response to pharmacologic stress Rb-82 PET. J Nucl Cardiol (2014) 1.46
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res (2008) 1.43
Posterior lumbar vein off the retrohepatic inferior vena cava: a novel anatomical variant with surgical implications. J Urol (2011) 1.43
Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs. N Engl J Med (2006) 1.42
Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP-2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem (2003) 1.41
Cost-effectiveness of percutaneous coronary intervention in optimally treated stable coronary patients. Circ Cardiovasc Qual Outcomes (2008) 1.40
Negative regulation of Lck by Cbl ubiquitin ligase. Proc Natl Acad Sci U S A (2002) 1.40
Protein tyrosine kinase regulation by ubiquitination: critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta (2012) 1.39
Baseline fractional flow reserve and stent diameter predict optimal post-stent fractional flow reserve and major adverse cardiac events after bare-metal stent deployment. JACC Cardiovasc Interv (2009) 1.39
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem (2003) 1.39
Human papillomavirus oncoprotein E6 inactivates the transcriptional coactivator human ADA3. Mol Cell Biol (2002) 1.38
The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation. Mol Biol Cell (2005) 1.36
Src-like adaptor protein regulates TCR expression on thymocytes by linking the ubiquitin ligase c-Cbl to the TCR complex. Nat Immunol (2005) 1.35
A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc Natl Acad Sci U S A (2008) 1.33
The notch regulator MAML1 interacts with p53 and functions as a coactivator. J Biol Chem (2007) 1.33
Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res (2006) 1.32
Human papilloma virus 16 E6 oncoprotein inhibits retinoic X receptor-mediated transactivation by targeting human ADA3 coactivator. J Biol Chem (2002) 1.32
VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res (2009) 1.32
Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res (2010) 1.32
The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol (2002) 1.32
The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res (2008) 1.31
Microdeformational wound therapy: effects on angiogenesis and matrix metalloproteinases in chronic wounds of 3 debilitated patients. Ann Plast Surg (2006) 1.30
Histological, molecular and functional subtypes of breast cancers. Cancer Biol Ther (2010) 1.30
TULA: an SH3- and UBA-containing protein that binds to c-Cbl and ubiquitin. Oncogene (2004) 1.30
Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol Psychiatry (2008) 1.27
Mammary epithelial cell transformation: insights from cell culture and mouse models. Breast Cancer Res (2005) 1.26
Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med (2002) 1.25
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
Tyrosine phosphorylation of Sprouty proteins regulates their ability to inhibit growth factor signaling: a dual feedback loop. Mol Biol Cell (2004) 1.24
Quality of life in autosomal dominant polycystic kidney disease patients not yet on dialysis. Clin J Am Soc Nephrol (2009) 1.24
Radiation abscopal antitumor effect is mediated through p53. Cancer Res (2003) 1.22
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A (2004) 1.22
Negative regulation of EphA2 receptor by Cbl. Biochem Biophys Res Commun (2002) 1.21
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy. J Clin Oncol (2004) 1.21
Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts. Cancer Res (2008) 1.20
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer (2007) 1.19
Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol (2008) 1.17
CHIP and HSPs interact with beta-APP in a proteasome-dependent manner and influence Abeta metabolism. Hum Mol Genet (2007) 1.16
Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol (2007) 1.16
Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment. Cancer Epidemiol Biomarkers Prev (2008) 1.16
Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells. Am J Respir Cell Mol Biol (2009) 1.15